News

The investigator at the Healey & AMG Center for ALS spoke to the newly released findings of the phase 2/3 trial of the investigational combination ALS agent AMX0035.

The researchers noted that future studies should examine the cost-effectiveness of CT compared with MRI as the best initial imaging modality for mechanical thrombectomy.

Findings suggest that compared with isolated cases, both earlier age at initial episode and a higher prevalence of personal and family history of migraine are linked to TGA recurrence.

The chief research officer and epilepsy specialist at Cleveland Clinic detailed the reasons why epilepsy surgery is not utilized as often as it should, and her efforts to raise awareness.

Data from the CENTAUR trial showed that the monthly rate of decline measured by ALSFR-S was 0.42 points slower for patients treated with the combination agent AMX0035.

The chief medical officer at Cure SMA detailed the importance of having various treatment options for patients, particularly for adults with SMA.

The findings support the integration of sleep assessments into routine developmental screenings in school and primary care settings.

The FDA-approved epilepsy monotherapy showed significant reductions in primary generalized tonic-clonic seizures of ≥50% and ≥75% from baseline.

A low glycemic index therapy diet is associated with the least number of and least severe adverse events among all 3 epileptic diet methods, with similar reductions in seizure burden.

The FDA-approved agent showed significant impact in decreasing standard deviation of lateral position, a measure used to assess driving performance.

Pooled data from 2 clinical trials of the H3-receptor antagonist/inverse agonist show it improved cataplexy and excessive daytime sleepiness in patients with narcolepsy who were most hampered by symptoms.

The director of the Lou Ruvo Center for Brain Health and neurologist at Cleveland Clinic detailed the state of Alzheimer disease and what research particularly grabbed his attention at AAIC 2020.